Continuous Diaphragm Monitoring of mechanically ventilated patients

Informations projet

DiaMon

N° de convention de subvention: 768260

DOI

10.3030/768260

Projet clôturé

Date de signature de la CE 11 Juillet 2017

Date de début 1 Août 2017

Date de fin 31 Mars 2020

Financé au titre de

• SOCIETAL CHALLENGES - Health, demographic change and well-being

Coût total

€ 2 988 500,00

Contribution de l’UE

€ 2 988 500,00

Coordonné par

RESPINOR AS
Norway

Periodic Reporting for period 2 - DiaMon (Continuous Diaphragm Monitoring of mechanically ventilated patients)

Période du rapport: 2018-11-01 au 2020-03-31

Résumé du contexte et des objectifs généraux du projet

Respinor DXT (Diaphragm Excursion Technology) is a novel, non-invasive, ultrasound-based medical device for continuous monitoring of the diaphragm, the main breathing muscle. It provides real-time, continuous feedback and is operator independent.
It is highly important, both clinically and economically, to bring patients off Mechanical Ventilation (MV) and back to normal, spontaneous breathing as quickly as possible. There is currently a severe lack of accurate, cost-effective solutions to support the MV weaning process. Patients on MV are expensive patients, and our technology will provide significant cost benefits to the hospitals and society at large..
Respinor offers accurate and continuous monitoring of diaphragm movement and respiratory rate over time in a user-friendly and operator-independent manner to assist clinical decision-making regarding liberation from MV.
Respinor DXT provide an objective measure of breathing for critically ill patients on a continuous basis. An easy to use, per patient sensor kit which provides real-time information of diaphragm function and respiratory parameters.
To show clinical usefulness of Respinor DXT is the overall objective of this project.

Travail effectué depuis le début du projet jusqu’à la fin de la période considérée dans le rapport et principaux résultats atteints jusqu’à présent

Respinor has developed a new branding, identified our main challenges and tactical choices for 2018-19 and developed a communication plan. We have created an awareness campaign which we have presented at different meetings to increase awareness about our product offerings and secure that we capitalize on the momentum as the H2020 winner both in phase 1 and phase 2. To ensure successful commercial exploitation we’ve developed an overall exploitation plan. Our pre-launch activities are targeting key customers who initially are defined as: investors, principal investigators, KOLs and potential distribution partners.

On the technical side advances in the project has led to the preparation of new intellectual property the form of two new patent applications.

The company has obtained approval to conduct clinical feasibility studies at four sites in Europe within mechanical ventilation (MV).

Respinor DXT was exhibited for the first time at the ICU Recovery meeting in Leuven in November of 2018. Further Respinor DXT was given exposure both at the Norwegian-Chinese summit in Beijing in October 2018 and at a Norway Health Tech cluster meeting to Minneapolis, USA.

Progrès au-delà de l’état des connaissances et impact potentiel prévu (y compris l’impact socio-économique et les conséquences sociétales plus larges du projet jusqu’à présent)

Our technology has a broad range of potential benefits and represents an enabling technology platform for applications in critical care and other areas of respiratory medicine.

The current clinical studies aim to show that Respinor DXT has the potential to predict successful liberation from MV and to reduce the length of stay and potential morbidity associated with MV.

Respinor DXT is estimated to launch in the EU by the end of 2020 and expand into other key markets globally.

Respinor DXT is protected by several patents, patent applications and trademarks.

Image of Respinor DXT

Respinor logo